Ersefuryl, 200 mg capsules 14 pcs

Ersefuryl is an intestinal antiseptic, anti-diarrheal drug.

Like other nitrofurans it blocks some redox enzyme reactions in the cells of microorganisms.

When used in therapeutic doses it has a bacteriostatic effect, in high doses it is bactericidal. It is active against Gram-positive (Staphylococcus, Streptococcus, Clostridium) and Gram-negative (Escherichia coli, Salmonella, Shigella, Klebsiela, Enterobacter, Vibrio cholerae etc.) microorganisms. Does not affect saprophytic flora (does not cause dysbacteriosis). No resistance of bacterial strains develops to the drug.

Pharmacokinetics

Nifuroxazide is almost not absorbed from the gastrointestinal tract; 99% of the dose taken remains in the gut and has its antimicrobial effect there. Nifuroxazide is excreted by the intestine: 20% is unchanged and the remaining amount of nifuroxazide is chemically altered.

Indications

Acute bacterial diarrhea, proceeding without deterioration of general condition, increase in body temperature, intoxication (in addition to adequate severity of diarrhea rehydration by oral fluid and electrolytes administration or, if necessary, their intravenous administration).

Active ingredient

Composition

1 capsule contains:

the active ingredient:

nifuroxazide 200 mg;

auxiliary substances:

sucrose 72 mg,

magnesium stearate 1.8 mg,

corn starch 88 mg;

capsule shell composition:

gelatin, titanium dioxide, iron oxide yellow.

How to take, the dosage

Ersefuryl is taken orally. For adults or children over 6 years of age.

In adults, 4 capsules/day (800 mg) divided into 2-4 doses.

In children over 6 years of age, 3-4 capsules/day (600-800 mg) divided into 2-4 doses.

The duration of treatment is not more than 7 days.

Special Instructions

In the case of bacterial diarrhea with signs of systemic involvement (deterioration of general condition, elevated body temperature, symptoms of intoxication or infection), antibacterial agents with good systemic diffusion should be used.

In case of severe, prolonged diarrhea, severe vomiting, or refusal of food, intravenous administration of fluids and electrolytes for rehydration should be considered.

If diarrhea persists for more than 2 days after treatment, the need for oral or intravenous fluids and electrolytes should be considered. The volume of fluids given and the mode of administration (oral or intravenous) should be appropriate for the severity of the diarrhea, the patient’s age, and their clinical condition.

The effect on the ability to drive or perform work requiring increased speed of physical and mental reactions. The drug has no effect on the ability to drive vehicles or engage in other potentially hazardous activities.

Contraindications

Side effects

Allergic reactions such as skin rashes, urticaria, Quincke’s edema, or anaphylactic shock are extremely rare.

Pregnancy use

In animal studies no teratogenic effect has been detected with nifuroxazide.

However, as a precautionary measure, it is not recommended to take nifuroxazide during pregnancy (insufficient clinical experience of use in pregnancy).

Lactation period. During the period of lactation it is possible to continue breastfeeding in case of a short course of treatment with the drug.

Similarities